

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

Docket: 4239-61725

App: 09/830,748

Applicant: Kashmiri et al.

Filed: April 30, 2001

Art Unit: Not yet assigned

ATTACHED TO

1)

U.S. PATENT DOCUMENTS

Init.*	Number	Date	Name	Class	Sub	Filed
LD	4,816,567	3/28/89	Cabilly et al.	—	—	
	5,472,693	12/5/95	Gourlie et al.			
	5,482,040	1/9/96	Martin, Jr.			
	5,512,443	4/30/96	Schlom et al.			
	5,534,254	7/9/96	Huston et al.			
	5,585,089	12/17/96	Queen et al.			
	5,688,657	11/18/97	Tsang et al.			
LD	5,976,531	11/2/99	Mezes et al.	—	—	
LD	5,976,845	11/2/99	Mezes et al.	—	—	

RECEIVED
OCT 30 2002
TECH CENTER 1600/2900

U.S. PATENT APPLICATION DOCUMENTS

LD	08/961,309	10/30/97	Mezes et al.	—	—	
----	------------	----------	--------------	---	---	--

FOREIGN PATENT DOCUMENTS

Init.*	Number	Date	Country	Class	Sub	Filed
LD	2,131,355 X	4/17/01	Canada	—	—	
	EP0239400 X	9/30/87	EPO			
	EP0365997 X	5/2/90	EPO			
LD	WO 89/00692 X	1/26/89	WIPO	—	—	
LD	WO 89/01783 X	3/9/89	WIPO	—	—	

EXAMINER:

DATE

5/1/03

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

**INFORMATION DISCLOSURE
STATEMENT**

BY APPLICANT

Docket: 4239-61725

App: 09/830,748

Applicant: Kashmiri et al.

Filed: April 30, 2001

Art Unit: Not yet assigned

WO 90/04410	X	5/3/90	WIPO
WO 91/00295	X	1/10/91	WIPO
WO 93/12231	X	6/24/93	WIPO
WO 96/13594	X	5/9/96	WIPO
WO 97/26010	X	7/24/97	WIPO
WO 98/18809	X	5/7/98	WIPO
WO 99/43816	X	9/2/99	WIPO
WO 00/26394	X	5/11/00	WIPO

OTHER DOCUMENTS

Abergel et al., "Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab'," *Proteins: Structure, Function, and Genetics* 17:438-443, 1993. X

Colcher et al., "Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies," *Cancer Research* 48:4597-4603, August 15, 1988. X

Divgi et al., "Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen," *Nucl. Med. Biol.* 21(1):9-15, 1994. X

Hand et al., "Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma," *Cancer Supplement* 73(3):1105-1113, February 1, 1994. X

Iwahashi et al., "CDR Substitutions of a Humanized Monoclonal Antibody (CC49): Contributions of Individual CDRs to Antigen Binding and Immunogenicity," *Molecular Immunology* 36:1079-1091, 1999. X

Johnson et al., "Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3," *Cancer Research* 46:850-857, February 1986. X

EXAMINER:

DATE

5/1/03

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.



RECEIVED

OCT 3 0 2002

SAS:tij 08/15/2002 4239-61725 E-258-98/2

TECH CENTER 1600/2900

Docket: 4239-61725

App: 09/830,748


INFORMATION DISCLOSURE
STATEMENT

Applicant: Kashmiri et al.

BY APPLICANT

Filed: April 30, 2001

Art Unit: Not yet assigned



LA		Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse," <i>Nature</i> 321 :522-525, May 29, 1986.
		Kashmiri et al, "Generation, Characterization, and <i>in Vivo</i> Studies of Humanized Anticarcinoma Antibody CC49," <i>Hybridoma</i> 14 (5):461-473, 1995. X
		Mulligan et al., "Phase I Study of Intravenous ¹⁷⁷ Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma," <i>Clinical Cancer Research</i> 1 :1447-1454, December 1995. X
		Muraro et al., "Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen," <i>Cancer Research</i> 48 :4588-4596, August 15, 1988. X
		Padlan et al., "Identification of Specificity-determining Residues in Antibodies," <i>The FASEB Journal</i> 9 :133-139, January 1995. X
		Padlan, "A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains while Preserving their Ligand-binding Properties," <i>Molecular Immunology</i> 28 (4/5):489-498, 1991. X
		Rixon et al., "Preferential Use of a H Chain V Region in Antitumor-associated Glycoprotein-72 Monoclonal Antibodies," <i>The Journal of Immunology</i> 151 (11):6559-6568, December 1, 1993. X
		Sha et al., "A Heavy-chain Grafted Antibody that Recognizes the Tumor-associated TAG72 Antigen," <i>Cancer Biotherapy</i> 9 (4):341-349, 1994. X
W		Slavin-Chiorini et al., "Biological Properties of Chimeric Domain-deleted Anticarcinoma Immunoglobulins," <i>Cancer Research (Supplement)</i> 55 :5957s-5967s, December 1, 1995. X
BP		Tamura et al., "Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only," <i>Journal of Immunology</i> 164 (3):1432-1441, February 1, 2000. X

EXAMINER:

DATE

5/1/03

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

OCT 30 2002

TECH CENTER 1600/2900
Pocket: 4330

Docket: 4239-61725

App: 09/830,748

Applicant: Kashmiri et al.

Filed: April 30, 2001

Art Unit: Not yet assigned

LD

Xiang et al., "Complementarity Determining Region Residues Aspartic Acid at H55, Serine at H95 and Tyrosines at H97 and L96 Play Important Roles in the B72.3 Antibody-TAG72 Antigen Interaction," *Protein Engineering* **9**(6):539-543, June 1996.

40

Xiang et al., "The Tyrosine Residue at Position 97 in the V_H CDR3 Region of a Mouse/Human Chimeric Anti-Colorectal Carcinoma Antibody Contributes Hydrogen Bonding to the TAG72 Antigen," *Cancer Biotherapy* **8(3)**:253-262, 1993.

EXAMINER:

DATE _____

5/1/03

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

Date Made: August 30, 2001

Sheet 1 of 2

RECEIVED

DEC 10 2001

TECH CENTER 1600/2

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11613.32USWO


Application Number:

09/830,748

Applicant: KASHMIRI ET AL.

Filing Date: 04/30/2001

Group Art Unit: UNKNOWN



ATTACH TO # 13

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LA	4,816,567	03/28/1989	Cabilly et al.	—	—	
	5,472,693	12/05/1995	Gourlie et al.			
	5,482,040	01/09/1996	Martin, Jr.			
	5,512,443	04/30/1996	Schlom et al.			
	5,534,254	07/09/1996	Huston et al.			
	5,585,089	12/17/1996	Queen et al.			
LA	5,688,657	11/18/1997	Tsang et al.	—	—	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
LA	2,131,355	03/02/1996	CA	—	—		
	0 239 400	09/30/1987	EP				
	0 365 997	05/02/1990	EP				
	WO 89/00692	01/26/1989	PCT				
	WO 89/01783	03/09/1989	PCT				
	WO 90/04410	05/03/1990	PCT				
	WO 93/12231	06/24/1993	PCT				
	WO 96/13594	05/09/1996	PCT				
	WO 97/26010	07/24/1997	PCT				
	WO 98/18809	05/07/1998	PCT				
	WO 99/43816	09/02/1999	PCT				
LA	WO 00/26394	05/11/2000	PCT	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

LAH	Abergel, C. et al., "Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab", <i>PROTEINS: Structure, Function, and Genetics</i> , Vol. 17, pp. 438-443 (1993).
LAH	Colcher, D. et al., "Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies", <i>Cancer Research</i> , Vol. 48, pp. 4597-4603 (August 15, 1988).

EXAMINER

DATE CONSIDERED

5/1/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

Docket Number:

11613.32USWO

Application Number:

09/830,748


IN AN APPLICATION

(Use several sheets if necessary)

Applicant: KASHMIRI ET AL.

Filing Date: 04/30/2001

Group Art Unit: UNKNOWN



	Divgi, C. et al., "Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen", <i>Nucl. Med. Biol.</i> , Vol. 21, No. 1, pp. 9-15 (1994).
	Hand, P. et al., "Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma", <i>CANCER Supplement</i> , Vol. 73, No. 3, pp. 1105-1113 (February 1, 1994).
	Iwahashi, M. et al., "CDR Substitutions of a Humanized Monoclonal Antibody (CC49): Contributions of Individual CDRs to Antigen Binding and Immunogenicity", <i>Molecular Immunology</i> , Vol. 36, pp. 1079-1091 (1999).
	Johnson, V. et al., "Analysis of a Human Tumor-Associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3", <i>CANCER RESEARCH</i> , Vol. 46, pp. 850-857 (February 1986).
	Jones, P. et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse", <i>Nature</i> , Vol. 321, pp. 522-525 (May 29, 1986).
	Kashmiri, S. et al., "Generation, Characterization, and <i>in Vivo</i> Studies of Humanized Anticarcinoma Antibody CC49", <i>Hybridoma</i> , Vol. 14, No. 5, pp. 461-473 (1995).
	Mulligan, T. et al., "Phase I Study of Intravenous ¹⁷⁷ Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma", <i>Clinical Cancer Research</i> , Vol. 1, pp. 1447-1454 (December 1995).
	Muraro, R. et al., "Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen", <i>Cancer Research</i> , Vol. 48, pp. 4588-4596 (August 15, 1988).
	Padlan, E., "A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties", <i>Molecular Immunology</i> , Vol. 28, No. 4/5, pp. 489-498 (1991).
	Padlan, E. et al., "Identification of Specificity-Determining Residues in Antibodies", <i>Research Communications</i> , Vol. 9, pp. 133-139 (January 1995).
	Rixon, M. et al., "Preferential Use of a H Chain V Region in Antitumor-Associated Glycoprotein-72 Monoclonal Antibodies", <i>The Journal of Immunology</i> , Vol. 151, No. 11, pp. 6559-6568 (December 1, 1993).
	Sequence Listing from PCT Application PCT/US99/25552, "Variants of Humanized Anti-Carcinoma Monoclonal Antibody CC49", 12 pages (Filed October 29, 1999).
	Sha, Y. et al., "A Heavy-Chain Grafted Antibody that Recognizes the Tumor-Associated TAG72 Antigen", <i>Cancer Biotherapy</i> , Vol. 9, No. 4, pp. 341-349 (Winter 1994).
	Slavin-Chiorini, D. et al., "Biological Properties of Chimeric Domain-deleted Anticarcinoma Immunoglobulins", <i>Cancer Research (Suppl.)</i> , Vol. 55, pp. 5957s-5967s (December 1, 1995).
	Tamura, M. et al., "Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only", <i>The Journal of Immunology</i> , Vol. 164, No. 3, pp. 1432-1441 (February 1, 2000).
	Xiang, J. et al., "Complementarity Determining Region Residues Aspartic Acid at H55, Serine at H95 and Tyrosines at H97 and L96 Play Important Roles in the B72.3 Antibody-TAG72 Antigen Interaction", <i>Protein Engineering</i> , Vol. 9, No. 6, pp. 539-543 (June 1996).
	Xiang, J. et al., "The Tyrosine Residue at Position 97 in the V _H CDR3 Region of a Mouse/Human Chimeric Anti-Colorectal Carcinoma Antibody Contributes Hydrogen Bonding to the TAG72 Antigen", <i>Cancer Biotherapy</i> , Vol. 8, No. 3, pp. 253-262 (Fall 1993).



23552

PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.